He spends two million a year on Blueprint. He claims he’s aging slower than the average 17-year-old. He shows up shirtless on every podcast in the country. We ran his protocol through the BS Detector. Here is what is actually backed by science, what is reasonable but unproven, and what is essentially expensive theater.
Bryan Johnson is the easiest person on the internet to either worship or mock. He’s spent reported sums in the eight figures on the most ambitious anti-aging experiment any individual has ever publicly attempted. The vast majority of his protocol is wrong for you. A small, important part of it is exactly right.
If you’ve seen the headlines — he claims his epigenetic age is 17 years younger than his chronological one, he goes to bed at 8:30pm, he eats his last meal at 11am, his son donated him a liter of plasma — you’ve probably also wondered: is any of this real? And could it scale down to a normal life and a normal budget?
This page runs the public version of his Blueprint protocol through the BS Detector and the Evidence Grade framework we apply to every health claim. We’re not here to dunk on him — he’s funded interesting research and made longevity culturally legible — but we are here to separate the well-evidenced moves from the marketing.
Johnson’s Blueprint protocol (he’s open about it; it’s published at blueprint.bryanjohnson.com) involves roughly five categories:
Reported annual cost: ~$2 million. He frames the whole thing as a public experiment, not a product. (He sells a Blueprint supplement and food line and launched a Blueprint biological age test in February 2025 at around $365/year; we’re not evaluating those products here.)
Strip the protocol back to its bones and the parts that almost certainly drive his measurable improvements are unsexy and inexpensive.
Decades of large cohort and meta-analytic evidence show that regular sleep, vigorous exercise (especially the resistance training he includes), a vegetable-forward diet adequate in protein, and a normal calorie load are the dominant levers in healthy aging. None of these require anything Johnson does that you couldn’t do for ~$500 a year. (For the citations on each of these, see our 9 Things That Actually Work series.)
His sleep regularity in particular — same bedtime, same wake time, measured continuously — is one of the few habits with direct mortality evidence from large cohorts (Windred et al., Sleep, 2024). Sleep regularity actually outperforms sleep duration as a mortality predictor. He nails this and most people don’t.
His aggressive sun protection sounds extreme (hat, hoodie, hand covering, indoor exercise), but the skin-aging effect of UV exposure is well-evidenced (Flament et al., Skin Research and Technology, 2013). For someone whose entire public brand is biological age, this is rational. For an average over-50 adult who lives in sunlight and gets vitamin D from it, it’s overkill.
His biomarker tracking discipline — checking 30+ markers monthly — is the part most worth copying in spirit, even if you do it at 1/100th the scale. Knowing your fasting insulin, ApoB, hsCRP, vitamin D, B12, ferritin, and thyroid panel once a year tells you more than 95% of the supplements you might buy.
What this means for you: If you copy three things from Bryan Johnson and ignore everything else, copy these — consistent sleep schedule with tracking, daily resistance training plus aerobic exercise, and annual or twice-yearly blood biomarker checks. Total cost: well under $1,000/year, often free.
Several pieces of his protocol have plausible mechanisms and early evidence, but no published longevity outcome in humans. These are bets, not conclusions.
The case: Rapamycin (sirolimus) is the single most-studied compound in animal longevity research. It extends median lifespan by 9–14% in mice (Selvarani et al., GeroScience, 2020). The PEARL trial published in April 2025 (Mannick & Lamming, Aging (Albany NY)) was the largest randomized human study to date — n=114, 48 weeks, 5 mg or 10 mg compounded rapamycin weekly. The primary endpoint — change in visceral adiposity — did not meet statistical significance (p=0.942). Secondary signals emerged in subsets (modest lean mass and pain improvement in women on 10 mg). A critical caveat: the compounded formulation tested had about one-third the bioavailability of commercial sirolimus.
What Johnson did: He publicly dropped rapamycin in 2024 after concluding the side effects outweighed his personal benefit signal. That decision predated PEARL’s primary endpoint failure but arguably anticipated it.
Honest verdict: The case has weakened. PEARL is real negative evidence on the primary outcome, even with the bioavailability caveat. Not a recommendation for adults over 50 outside a research setting.
The case: NAD+ declines with age. Mouse studies on NMN and NR show varied benefits. Human RCTs (Martens et al., Nature Communications, 2018; Yoshino et al., Science, 2021) show NMN and NR can raise NAD+ levels and produce modest functional changes — muscle insulin sensitivity in one group, mild aerobic capacity changes in another. No human study has shown biological age reversal, lifespan extension, or major clinical outcomes.
Honest verdict: Heavily marketed, modestly evidenced. The gap between what mouse studies suggest and what human trials have shown is the entire story.
The case: CGM use is sold as a window into “metabolic health” for non-diabetic adults. Some evidence that seeing your glucose response helps with food choices behaviorally. No RCT has shown CGM-guided dietary changes improve long-term health outcomes in non-diabetics. Most metabolically healthy adults have small post-meal glucose excursions that don’t mean anything clinically.
Honest verdict: Interesting biofeedback tool. Not a longevity intervention.
Some pieces of the Blueprint protocol have weak-to-zero supporting human evidence and are best understood as expensive curiosity-driven experiments rather than recommendations.
Johnson’s 2023 son-to-father plasma exchange experiment was widely-covered and widely-mocked. On January 28, 2025 he publicly announced he had ended the son-blood injections (he had already conceded in a mid-2023 Fortune interview that he saw “no benefits” from them) and pivoted to bi-weekly Total Plasma Exchange (TPE) with 5% albumin plus IVIG. So this isn’t a clean “discontinued” story — it’s a pivot to a more clinically grounded procedure. Published research on plasma exchange and parabiosis for human aging remains inconclusive with no clear longevity benefit demonstrated in controlled trials (Lyons & Ulffers, Journals of Gerontology A, 2022). Mouse heterochronic parabiosis produces interesting rejuvenation effects, but the human translation remains unproven and the procedure carries real medical risk. A 2025 RCT cohort of TPE for HIV-lipohypertrophy showed some epigenetic-clock movement, but the population is too narrow to generalize.
Johnson has publicly tried experimental gene therapies (notably follistatin gene therapy administered abroad in 2023). No published evidence supports longevity benefit in humans; safety data is preliminary at best. This is experimentation, not intervention. Reasonable people draw very different conclusions about whether one healthy individual should be doing this.
Some individual supplements in his stack have solid evidence (creatine, omega-3, D3, magnesium). Many do not (NMN, urolithin A megadosing, lithium orotate, taurine in mega-doses). The aggregate effect of taking 50+ supplements daily has never been studied, the interaction profile is unknown, and several have plausibly meaningful drug-supplement interaction risks (see our Anti-Aging Reality Check free report for the dangerous-interaction list). Most well-evidenced longevity benefit is in the food, not the powder.
Three things outside the protocol itself moved the public conversation about Johnson in 2025-2026. None of them validate or refute the science of what he does, but they sharpen what an over-50 reader should weight when reading his claims.
None of this changes whether rapamycin extends mouse lifespan or whether NMN raises NAD+ levels. It does mean that “Bryan Johnson said it works” carries less weight in 2026 than it did in 2024.
| From the Blueprint protocol | Verdict |
|---|---|
| Consistent sleep schedule + sleep tracking | Copy. Strong human evidence for sleep regularity and mortality. |
| Daily vigorous exercise + resistance training | Copy. Among the best-evidenced interventions in this entire field. |
| Plant-forward calorie-controlled diet, adequate protein | Copy the shape, not the rigidity. The Mediterranean pattern gets you most of the benefit. |
| Time-restricted eating (last meal at 11am) | Reasonable but unproven. Earlier eating windows have some metabolic evidence; the 11am cutoff is personal preference. |
| Annual or quarterly biomarker tracking | Copy in spirit at 1/100th the scale. Annual blood panel is enough for most. |
| Aggressive sun protection | Skin-aging evidence is solid; copy the principle, not the monasticism. |
| Rapamycin (off-label, low-dose intermittent) | Skip / wait. Johnson dropped it in 2024; PEARL trial primary endpoint failed in April 2025. Animal evidence still strong, human evidence is weaker than 2024 ballparks suggested. |
| NMN / NR megadosing | Hyped well past the human evidence. Skip until trials catch up. |
| Continuous glucose monitor (non-diabetic) | Interesting biofeedback. Not a longevity intervention. |
| ~50 supplements daily | A small subset (creatine, omega-3, D3, magnesium) is worth taking. Most are noise. Aggregate effect unknown. |
| Son-blood injections | Skip. Johnson himself ended these in January 2025 after conceding no benefit. |
| Total Plasma Exchange (TPE) with albumin + IVIG | Skip outside research. Johnson’s January 2025 pivot. Human longevity evidence remains inconclusive; some narrow-population epigenetic signal exists. |
| Experimental gene therapy | Skip. Experimentation, not intervention. |
The bigger frame. Bryan Johnson is unusually disciplined about the basics. He is also doing extremely expensive, experimental things that aren’t backed by human evidence yet. What you read in headlines (“He stopped aging!”) is almost always about the fundamentals doing what fundamentals do, not the exotic interventions. The lesson isn’t “copy Bryan Johnson.” The lesson is: the boring stuff actually works, and almost nobody does it consistently.
The Over-50 Reverse-Aging Guide collects every intervention worth doing, every claim that didn’t survive scrutiny, and the exact dosages backed by human RCTs.
See the Full GuideIt depends what “work” means. His self-reported biomarkers and epigenetic age tests have moved favorably. But the protocol mixes well-evidenced fundamentals (sleep, exercise, diet, measurement) with weakly-evidenced supplements and procedures (rapamycin off-label, plasma exchange, NMN megadosing). The fundamentals are doing most of the work, and you can copy those for under $500/year.
Approximately $2 million per year, by his own public reporting — covering supplements, prescription medications, MRIs, biomarker tracking, dental and cosmetic work, and clinical procedures.
The boring, well-evidenced parts: a consistent sleep schedule with sleep tracking, daily vigorous exercise including resistance training, a calorie-controlled plant-forward diet adequate in protein, regular biomarker measurement, and sensible sun protection. These are responsible for most of his measurable improvements and cost almost nothing.
No. The PEARL trial published in April 2025 (n=114, 48 weeks) failed its primary endpoint (visceral adiposity, p=0.942). Secondary signals emerged in subsets. A bioavailability caveat: the compounded formulation had about one-third the bioavailability of commercial sirolimus. Johnson himself dropped rapamycin from his protocol in 2024 citing side effects. The animal evidence (9–14% mouse lifespan extension) is still strong; the human case is weaker than 2024 ballparks suggested.
Johnson ended the son-to-father blood injections on January 28, 2025 after publicly conceding earlier that he saw no benefits. But this was a pivot, not an abandonment — he switched to bi-weekly Total Plasma Exchange (TPE) with 5% albumin plus IVIG. Published research on plasma exchange for human aging remains inconclusive.
Three things sharpened the picture: the Netflix Don’t Die documentary (January 2025) drew mixed reviews and featured Harvard’s Vadim Gladyshev calling Johnson’s work “not science, just attention”; a March 2025 NYT investigation detailed his NDA use and Blueprint workplace disputes; hepatologist Cyriac Abby Philips publicly called Johnson a fraud. Independent third-party testing of Blueprint products by Tamara Rubin in June 2025 found the olive oil clean but flagged other products as having “concerning toxicant levels.”
His reported epigenetic age tests put his biological age younger than his chronological age, by various amounts depending on the specific test (Horvath, GrimAge, PhenoAge, DunedinPACE). These tests are useful research tools but are not a direct measurement of “true” aging — they correlate with mortality at the population level but their precision at the individual level is still being established. Headlines like “aging slower than a 17-year-old” should be read as “some clocks show favorable readings on his data,” not as a literal claim.
— Scott Covert, 60, skeptic, not a physician. I’m not anti-Bryan Johnson. He has made longevity culturally legible in a way nobody else has, and he’s honest about what he’s spending. I just want adults over 50 to know which parts are worth copying, which parts are experiments, and which parts are theater. Got a claim from his protocol you want run through the BS Detector? Tell me and I’ll dig in.